Compass Pathways Surges as BTIG Reaffirms Buy Rating and Trump’s Psychedelic Executive Order Sparks Sector Rally
BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.
/ 5 items
#CMPS↓
Trump to Launch Federal Research on Psychedelic Drug Ibogaine for PTSD
Trump plans to boost research on ibogaine for PTSD in veterans, despite safety concerns and its illegal status in the US.
Psilocybin Meets the Bar: Compass Pathways' Dual Phase 3 Wins Signal FDA Filing Ahead
Compass Pathways’ COMP360 psilocybin therapy succeeded in two Phase 3 trials for treatment-resistant depression. Fast relief, lasting effects, and good safety profile – could be the first psilocybin medicine approved by FDA.
Compass Pathways Advances PTSD Treatment and Prepares for Depression Launch
Compass Pathways receives FDA approval to begin late-stage PTSD trials with COMP360 psilocybin treatment while preparing for potential 2026 launch for treatment-resistant depression.
Oppenheimer Upgrades Compass Pathways on Growing Confidence in COMP360
Oppenheimer upgrades Compass Pathways to Outperform with a $15 target, citing rising conviction that COMP360 psilocybin therapy could become the first FDA-approved psychedelic treatment for depression.